No Data
The Hong Kong stock market is restructuring the value of pharmaceuticals! Hengrui Medicine has received a premium binding from AstraZeneca, and the stock price once rose over 20%.
① Does the offshore strategy mean that "technology platform premium + international certification" is replacing the traditional PE valuation method as the core logic for valuing Innovative Drugs companies? ② With JACOBIO-B narrowing its annual loss by 56.6% through its core product Galidesivir, can it be inferred that China’s Innovative Drugs companies have broken through the industry curse of "burning money on R&D - ongoing losses"?
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
The first subject has been administered in the Phase III clinical study of INNOVENT BIO IBI354 (an innovative HER2 ADC) for the treatment of platinum-resistant ovarian cancer.
San Francisco, USA and Suzhou, China, March 24, 2025 /PR Newswire/ -- INNOVENT BIO (Hong Kong Stock Exchange stock code: 01801), a biopharmaceutical company dedicated to the research, development, production, and sales of Innovative Drugs for major disease areas such as oncology, autoimmune diseases, metabolism, and ophthalmology, announced a randomized, controlled, multi-center Phase III clinical study (HeriCare) of IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate, HER2 ADC) for the treatment of patients with platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer expressing HER2.
INNOVENT BIO (01801) plans to include its new cancer drug as a breakthrough therapy.
IBI363 transforms "cold tumors" into "hot tumors" through a dual mechanism of PD-1 and IL-2, and has shown encouraging efficacy and good tolerance in phase 1a/1b and phase 2 studies, promising to become a new immunotherapy for malignant melanoma.
How strong are the Hong Kong pharmaceutical stocks right now? The Innovative Drugs Index has risen over 30% this year, reaching a near 16-month high.
① The Innovative Drugs Index in the Hong Kong stock market has increased by over 30% this year; why can it compete with Technology stocks? ② There has been a "small peak" in the commercialization of individual stocks; how do Institutions perceive the future market direction?
Hutchmed, Innovent Combo Therapy Hits PFS Target in Renal Cancer Study
